GlobalData Reports Sales for Big Pharma Companies Have Increased Due to COVID-19
GlobalData, a leading data and analytics company, has found that the COVID-19 pandemic has led to temporarily increased drug sales for big bio/pharma companies in the first quarter (Q1) of 2020. This increase was due to people stockpiling in preparation for limited medical access during the lockdown.
GlobalData’s Pharma Intelligence Center Drug Sales and Forecast Database reveals that global sales in Q1 2020 for companies that were not developing a COVID-19 drug saw an 8% increase in sales when compared to the archived global sales forecast for the same time period. In contrast, companies that were developing a COVID-19 drug only saw a 3% increase.
For more information, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
